The lupus erythematosus cell phenomenon is intimately connected with the pathogenesis and clinical results of therapy of systemic lupus erythematosus. A method has been devised for quantitatively assaying in vitro the effects of various chemicals upon this phenomenon. Detailed observations of the inhibition of lupus erythematosus cell formation by quinacrine (Atabrine) are presented.
Prokoptchouk in 1940 introduced the use of quinacrine in the treatment of lupus erythematosus,1 and Popoff2 reported similar success. Since the recent report in the English literature by Page3 there have been a number of confirmatory studies.* One of the cases in Page's series had active systemic lupus, which responded well to 200 mg. of quinacrine daily. In view of this and the evidence that systemic lupus erythematosus is a malignant form of the discoid variety, it seemed important to study the use of quinacrine (Mepacrine) in the generalized
DUBOIS EL. Effect of Quinacrine (Atabrine) upon Lupus Erythematosus Phenomenon. AMA Arch Derm. 1955;71(5):570–574. doi:10.1001/archderm.1955.01540290010002
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: